m8magic wrote: posted on facebook and asked all my friends to share and asked them to ask all their friend to share and on and on...
its worth a shot fella's to get someone to see that a jv into this is worth a risk...it doesn;t even have to be a pharma...it could be a guy like Sprott,Guistra..etc...any venture capitalist that could see the benefits of phase to for a relitively little sum (25 million drill programs are raised very often.)...so anyway below is what i posted and this could really take off on facebook and reach all the corners of the would through the friend network so i suggest all on this board do the same..
Big pharma doesn;t need to let you die..
don;t let it kill this company...Friends please share this with your friends and ask them to share and their friends to share. Otherwise this promising company will fall to the greed of big pharma.
Read up on the non intrusive, chemo and radiation free and cancer free results to date in its phase one trails and the potential this company is proving and please share and share.
Theralase PDT Technology Used to Treat First Patient for Bladder Cancer
Toronto, Ontario – April 4, 2017
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) , a leading biotech company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the first patient was treated on March 30, 2017 for Non-Muscle Invasive Bladder (“NMIBC”) cancer using its novel Photo Dynamic Therapy (“PDT”) technology.
Theralase PDT Technology Used to Treat Fourth Patient for Bladder Cancer
Toronto, Ontario – August 1, 2017
Theralase Successfully Achieves Primary and Secondary Objectives for First Three Patients Treated Using Anti-Cancer Technology for Bladder Cancer
Toronto, Ontario – May 26, 2017
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotechnology company focused on the commercialization of medical devices to eliminate pain and the development of Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the independent Data and Safety Monitoring Board (“DSMB”) has unanimously decided that the primary and secondary objectives for the first part of the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) have successfully been met.
May 30th 2018
Theralase Successfully Completes Phase Ib Non-Muscle Invasive Bladder Cancer Clinical Study
Theralase Medical and Scientific Advisory Board concluded that the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”) has met its objectives and unanimously voted for the early termination of the Study based on successfully achieving its primary and secondary endpoints after six patients.
The MSAB recommendation to the Company was to terminate the Study based on the six patients treated to date and suggested that the Company pursue a pivotal Phase II NMIBC clinical study approval with Health Canada and the FDA with efficacy as the primary endpoint.
The exploratory endpoint of efficacy is extremely encouraging as the fifth and sixth patients are clinically cancer free as of the ninety day cystoscopy examination."
Study Outcome Endpoints:
1) Primary: Evaluate safety and tolerability. (Measured by patients who experience Adverse Events (“AEs”) Grade 4 or greater that do not resolve within thirty (30) days; whereby: Grade 1 = Mild AE, Grade 2 = Moderate AE, Grade 3 = Severe AE, Grade 4 = Life-threatening or disabling AE, Grade 5 = Death)
2) Secondary: Evaluate the pharmacokinetics. (Movement and exit of drug within tissue) of TLD-1433 (Measured by TLD-1433 concentration levels in plasma and urine over 72 hours.)
3) Exploratory: Evaluate efficacy. (Measured by Recurrence Free Survival (“RFS”), defined as the interval from Day 0 (Day of PDT treatment) to documented recurrence or death from any cause, whichever occurs first. Recurrence is defined as any new tumour growth (i.e.: any biopsy-confirmed new or recurrent tumour), evaluated at 90 days for the first three patients treated at the MRSD and primarily at 90 days for the last six patients treated at the Therapeutic Dose and secondarily at 180 days post treatment.)
The Company is planning to meet with Health Canada and FDA, to discuss and finalize the design of a Health Canada and FDA pivotal Phase II NMIBC clinical study, with a primary endpoint of efficacy
Theralase® Discovers Cannabinoid Increases Efficacy of Patented Anti-Cancer Technology in Destruction of Brain Cancer
Toronto, Ontario – March 27, 2018
Theralase® Anti-Cancer Technology Effective in Destroying Brain Cancer Stem Cells
Toronto, Ontario – March 15, 2018
Theralase® Advances Anti-Cancer Technology in Destruction of Human Lung Cancer
Toronto, Ontario – March 5, 2018
Theralase® Anti-Cancer Vaccine Validated in Colorectal Cancer
Toronto, Ontario – November 22, 2017
Theralase Lead Anti-Cancer Drug Effective in the Destruction of Throat Cancer
Toronto, Ontario – September 19, 2017
Theralase Anti-Cancer Drugs Effective in the Destruction of Cervical Cancer
Toronto, Ontario – September 5, 2017